STAT3-IN-47 

STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma^[1].

STAT3-IN-47 (Compound S1) (0.1-10 μM) exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells, with IC₅₀ values of 5.066 μM, 0.8089 μM, 1.970 μM, and 1.412 μM respectively^[1].
STAT3-IN-47 (0.1-10 μM) suppresses STAT3 activation in a dose-dependent manner in HeLa, HepG2, U87, and LN229 cells^[1].
STAT3-IN-47 (0.5-2 μM) inhibits EGF-induced STAT3 phosphorylation (Y705) in HeLa cells and dose-dependently suppresses IL-6-induced STAT3 phosphorylation (Y705) in HepG2, U87, LN229 cells^[1].
STAT3-IN-47 downregulates stemness-associated genes (Nanog, Oct4, β-catenin) in Huh7, LN229, and HepG2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

324.31

C₁₅H₈N₄O₃S

2787548-58-5

O=C(C1=C2OC(/C=N/N3C=NNC3=S)=C1)C4=C(C2=O)C=CC=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yin K, et al. Discovery of novel 1,2,4-triazole schiff bases hybridized with 1,4-naphthoquinones as potent STAT3 inhibitors. Bioorg Chem. 2025 Aug 30;165:108936.  [Content Brief]